SLN
HOLD / NEUTRALMeanRevComposite
59.10
Technical
97.50
Fundamental
46.30
Rank
—
Price
15.43
Hurst
0.27
As of
Aug 11, 2026
Daily
Silence Therapeutics plc
HealthcareBiotechnologySilence Therapeutics is a biotechnology firm developing RNA-based therapies designed to silence disease-causing genes across blood disorders, heart disease, and uncommon conditions. The company's pipeline includes candidates targeting polycythemia vera, kidney diseases related to complement dysfunction, elevated lipoprotein(a) in cardiovascular patients, high cholesterol, abnormal blood lipids, and obesity, with several programs currently in clinical development stages.
Market cap
$789.4M
P/E (trailing)
—
P/E (forward)
-33.42
PEG ratio
—
Dividend yield
—
Beta
1.44
52w range
4.19 – 17.58
Return on equity
-90.41%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 12.50 (+148.5%) · range 4.30–15.43
Cycle position
56/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 10 · NOT READY · exit proximity 15
Conviction
22/ 100 · maturity 100%
VScore.408
Buildup.2047
EMA entry setup.2510
Fundamentals.1546
Volume profile
POC
13.60
Price vs POC
-8.1%
Overhead supply
53%
Runway
+6.8%
Value area 10.14–17.58 · 53% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Sep 8, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -7.95% | +0.48% | mature |
| 40d | -11.55% | +0.48% | 22/40d |